Celldex Therapeutics Inc CLDX Stock Analysis
- Nasdaq
- Stock
- After hours · opens Monday 9:30 AM ET
$29.28 up $1.01, 3.57% on Nov 6
Last price · Previous close $28.27
- Market cap
- $2.30BAt the last price
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$4.36Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$29.28up $1.01, 3.57%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$28.27Nov 5
- Volume1.11MNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.15MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $22.10 to $45.14; now $29.28
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the last price. Total return includes reinvested dividends.Price change only, without dividends.
| Period | CLDX |
|---|---|
| Short term | |
| 1M | CLDX: down 5.6% |
| 3M | CLDX: down 29.5% |
| YTD | CLDX: up 7.8% |
| 1Y | CLDX: up 25.9% |
| Long term | |
| 3Y | CLDX: down 0.2% −0.1% a year |
| 5Y | CLDX: down 36.2% −8.6% a year |
| 10Y | CLDX: down 36.8% −4.5% a year |
$10,000 invested in CLDX 10 years ago (Nov 4, 2016) would be worth about $6,317 as of , with dividends reinvested.
| Period | CLDX |
|---|---|
| Short term | |
| 1M | CLDX: down 5.6% |
| 3M | CLDX: down 29.5% |
| YTD | CLDX: up 7.8% |
| 1Y | CLDX: up 25.9% |
| Long term | |
| 3Y | CLDX: down 0.2% −0.1% a year |
| 5Y | CLDX: down 36.2% −8.6% a year |
| 10Y | CLDX: down 36.8% −4.5% a year |
$10,000 invested in CLDX 10 years ago (Nov 4, 2016) would be worth about $6,317 as of , not counting dividends.
All-time high
$3,015.00
Closing high on . Now 99.0% below that record.
Split-adjusted daily closes since Mar 26, 1990.
Stock splits
2
Latest: 1-for-15 on . Share counts adjust after each split.
Both splits
- 1-for-15
- 1-for-12
Valuation
The last price compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$4.36 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 14,545.9×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 3.2×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −10.53%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $1.59BAt the last price
What it would cost to buy the whole business: the market cap at the last price, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own CLDX DCF in Excel. Value Celldex Therapeutics with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $158.00Kdown 97.3%
- Net income
- −$300.55M
- Diluted EPS
- −$4.36
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $3.19M | −$42.12M | −$0.64 |
| Q4 FY24 (Dec 31, 2024) | $1.18M | −$47.09M | −$0.71 |
| Q1 FY25 (Mar 31, 2025) | $695.00K | −$53.80M | −$0.81 |
| Q2 FY25 (Jun 30, 2025) | $730.00K | −$56.60M | −$0.85 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$67.04M | −$1.01 |
| Q4 FY25 (Dec 31, 2025) | $121.00K | −$81.32M | −$1.23 |
| Q1 FY26 (Mar 31, 2026) | $15.00K | −$78.69M | −$1.18 |
| Q2 FY26 (Jun 30, 2026) | $22.00K | −$73.50M | −$0.94 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $4.65M | −$70.51M | −$1.64 |
| FY22 (Dec 31, 2022) | $2.36M | −$112.33M | −$2.40 |
| FY23 (Dec 31, 2023) | $6.88M | −$141.43M | −$2.92 |
| FY24 (Dec 31, 2024) | $7.02M | −$157.86M | −$2.45 |
| FY25 (Dec 31, 2025) | $1.55M | −$258.76M | −$3.90 |
Margins
- Gross 100.0%
- Operating −206,220.3%
- Net −190,220.9%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$242.11MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$235.57MLast 12 months
- Capital spending$6.54MLast 12 months
- −153,231.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $327.11MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $717.59MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$4.90MAs of Jun 30, 2026
- Net cash$712.68MAs of Jun 30, 2026
- 11.82As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.01As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 1 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −52.4%Last 12 months
Over the last 12 months, Celldex Therapeutics lost money: its net loss was 52.4% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −47.6%Last 12 months
Over the last 12 months, Celldex Therapeutics’s net loss was 47.6% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Celldex Therapeutics Inc
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New Jersey, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CLDX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CLDX stock FAQ
What is CLDX stock’s price today?
Celldex Therapeutics (CLDX) traded at $29.28 as of , up $1.01 (3.57%) from the previous close of $28.27. Over the past 52 weeks it has traded between $22.10 and $45.14.
If you invested $1,000 in CLDX 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CLDX on would be worth about $632 as of , a total return of −36.8%. The same $1,000 would be worth $638 if invested five years ago, $1,259 if invested one year ago, $120 if invested 20 years ago, and $81 if invested 30 years ago. Past performance doesn’t predict future returns.
What is Celldex Therapeutics’s market cap?
Celldex Therapeutics’s market capitalization is about $2.3 billion. That’s Tiingo’s daily market cap for , scaled to the last price of $29.28 on (how market cap works). Celldex Therapeutics reported 78.49M shares outstanding at the end of its latest quarter ().
What is CLDX’s P/E ratio?
CLDX’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$4.36).
How much revenue does Celldex Therapeutics make?
Celldex Therapeutics reported $158.0 thousand of revenue over the four quarters to , down 97.3% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $22.0 thousand, down 97.0% from a year earlier.
Is Celldex Therapeutics profitable?
Not over the four quarters to . Celldex Therapeutics reported a net loss of $300.5 million across those four quarters on $158.0 thousand of revenue.
What are CLDX’s earnings per share?
CLDX’s diluted earnings per share were −$4.36 over the four quarters to , compared with −$3.01 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.94 per share, against −$0.85 a year earlier (how EPS works).
Does CLDX pay a dividend?
Celldex Therapeutics hasn’t paid a dividend in the last twelve months.
What is CLDX’s 52-week high and low?
Over the past 52 weeks CLDX has traded as low as $22.10 and as high as $45.14. At $29.28 as of , it is 35.1% below that high and 32.5% above the low.
What is CLDX’s all-time high?
CLDX’s highest closing price was $3,015.00 on , adjusted for stock splits. At $29.28 as of , it is 99.0% below that record.
Has CLDX stock ever split?
Yes, twice: 1-for-12 on ; 1-for-15 on .
How has CLDX stock performed?
Including dividends and measured to the last price on , CLDX has returned +7.8% so far this year and +25.9% over the past year, and −36.2% over five years (−8.6% a year). Past performance doesn’t predict future returns.
What sector and industry is Celldex Therapeutics in?
Celldex Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in New Jersey, USA.
What exchange does CLDX trade on?
Celldex Therapeutics trades on the Nasdaq under the ticker symbol CLDX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.